United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Montes Archimedes Acquisition Corp.

Here's how a drug discovery company and a coronavirus vaccine drugmaker can boost investors' portfolios.

2 Best Biotech Stocks to Buy Now

Pfizer reported Q1 earnings that beat expectations while raising full-year guidance.

Pfizer Stock Forecast: How To View Q1 Earnings

BioNTech SE

Parents are pleased, but the move won't change much for the drug companies from a financial perspective.

Pfizer and BioNTech's COVID-19 Vaccine Authorized by the FDA for Adolescents

The mRNA technology used to develop the Pfizer-BioNTech Covid-19 vaccine could help create "more potent" seasonal flu shots, Pfizer's Kathrin Jansen told CNBC.

Pfizer scientist says mRNA technology used for Covid vaccines could create 'more potent' seasonal flu shots

Children aged 12 to 15 could be able to get a COVID-19 vaccine as early as Thursday, a US Food and Drug Administration (FDA) official said. The FDA expanded the authorization for Pfizer-BioNTech's COVID-19 shot to include 12- to 15-year-olds on Monday, after first approving it for people aged 16 and older in late 2020.

Children aged 12 to 15 could start getting Pfizer's COVID-19 vaccine as soon as Thursday, FDA official says

AstraZeneca

Johnson & Johnson

Moderna

Novavax

The government is having issues with giving away its excess supply.

How Will the U.S. Glut of Coronavirus Vaccines Affect Manufacturers?

Electronic Arts

Hanesbrands

NortonLifeLock

TransDigm

Some of the stocks that may grab investor focus today are: Wall Street expects TransDigm Group Incorporated (NYSE: TDG) to report quarterly earnings at $2.51 per share on revenue of $1.17 billion before the opening bell. TransDigm shares fell 1.1% to close at $601.37 on Monday.

5 Stocks To Watch For May 11, 2021

US regulators have approved the Pfizer COVID-19 vaccine for use in children as young as 12.

US regulators authorise use of Pfizer COVID-19 vaccine for ages 12 to 15

The U.S. Food and Drug Administration on Monday approved the emergency use of Pfizer Inc. (NYSE: PFE) and BioNTech SE's (NASDAQ: BNTX) COVID-19 vaccine in adolescents aged between 12 to 15 years. What Happened: The FDA said it has amended the emergency use authorization (EUA) originally issued in December last year for administration of the vaccine in individuals 16 years of age and older.

Pfizer-BioNTech COVID-19 Vaccine Gets FDA Emergency Approval For Age Group 12-15

NIH Director Dr. Francis Collins says the FDA's emergency use authorization of Pfizer and BioNTech's Covid vaccine for kids ages 12 to 15 is “a big deal.”

‘It's a big deal' for America's push to reopen, says NIH Director on Pfizer vaccine approval for adolescents

The U.S. Food and Drug Administration has expanded the emergency use authorization for the Pfizer-BioNTech Covid-19 vaccine to include kids 12 to15 years old. That expands the Dec. 11, 2020 use authorization from individuals 16 years of age and older. It's the same dosage. It means a much bigger swathe of the U.S. population can...

FDA Authorizes Pfizer Covid Vaccine For Kids 12 To 15 Years Old

Anyone 12 years old or older will be able to get the jab.

FDA Expands Pfizer Coronavirus Vaccine Authorization For Adolescents

Americans aged 12 and up are now allowed to obtain the COVID-19 shot.

FDA authorizes Pfizer vaccine for children aged 12-15

FDA OKs use of Pfizer-BioNTech COVID-19 vaccine in kids ages 12 to 15

Teenagers in the US are now eligible for a leading coronavirus vaccine, as US regulators on Monday expanded the OK for Pfizer-BioNTech's COVID-19 shot to include 12- to 15-year-olds.  The two-dose vaccine was OK'd last December for anyone 16 years old and up. US health officials said they are prepared to soon start giving the shot to teenagers.

The US just authorized Pfizer-BioNTech's coronavirus vaccine for teenagers, making it the first COVID-19 shot OK'd for 12- to 15-year-olds

The FDA granting use of the shot in younger age groups will allow middle school-aged students to get vaccinated before school starts this fall.

FDA permits use of the Pfizer-BioNTech Covid vaccine in kids ages 12 to 15

Merck

England's drug-cost watchdog has shown a cold-shoulder to Pfizer Inc (NYSE: PFE) and Merck KGaA's (OTCMKTS: MKGAF) Bavencio (avelumab) as first-line maintenance therapy for urothelial cancer after platinum-based chemo. The PD-L1 inhibitor, therefore, won't be able to enjoy routine NHS reimbursement or coverage through the more complicated and restrictive Cancer Drugs Fund, said the National Institute for Health and Care Excellence (NICE).

UK's NICE Provisionally Rejects Coverage Of Pfizer-Merck KGaA's Bavencio As First-Line Therapy For Bladder Cancer

Morgan Stanley estimates Pfizer will rake in nearly $100 billion from COVID-19 vaccine sales over the next five years. Pfizer's COVID-19 vaccine will earn about $96.1 billion by 2025, primarily during this year and next when demand for vaccines is the highest, Morgan Stanley said in an analyst note released May 9.

Pfizer could sell nearly $100 billion worth of COVID-19 vaccines in the next five years, Morgan Stanley estimates (PFE)

The European Union hasn't made any new orders for AstraZeneca's COVID-19 vaccine beyond June, when the contract ends, said European internal market commissioner Thierry Breton.

EU won't renew AstraZeneca COVID-19 vaccine; Pfizer shot will take precedence

The block said on Sunday it hasn't renewed orders for the AstraZeneca vaccine, but announced a deal to buy as many as 1.8 billion doses of the Pfizer and BioNTech shot.

EU Ditches AstraZeneca Vaccine. It's Pivoting to Pfizer.

Bristol-Myers

PFE and BMY are among the best dividend growth healthcare stocks you can find.

Pfizer Or Bristol-Myers Squibb: Which Is A Better Buy?

Investors should be focused on long-term data.

6 Months Later, Pfizer and BioNTech's Vaccine Data Continues to Impress

Q1 2021 results impressed, with monumental upgrades to outlook. The company has reinvented itself, and is enjoying one of the best periods of its history.

Pfizer Is Increasingly Attractive - With Or Without The Vaccine

Strong growth in revenue and earnings wasn't the only story in the company's latest quarterly update.

Pfizer's CEO Makes a Prediction That Could Mean Huge Post-Pandemic Success

Pfizer's Viatris spinoff has made the stock harder to value. The fundamentals are attractive even with low growth.

News for Pfizer Stock (PFE)